Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Dystroglycanopathy and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for DAG1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DAG1 Alpha-subunit (ECD-Fc) / Beta-subunit Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View DAG1 Products |
| Gene Delivery | DAG1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to preserve alpha/beta cleavage and cell-surface conformation. |
View DAG1 Products |
| Benchmark Ab | Anti-DAG1 Recombinant Antibody (Sequence of IIH6 / Clinical Clones) Recombinant positive control for ligand-blocking and FACS assays. |
View DAG1 Products |
| Validator | DAG1 siRNA Set For knockdown verification in target-specificity assays. |
View DAG1 Products |
| Related Target A | LARGE1 Critical glycosyltransferase required for functional matriglycan synthesis on DAG1. |
View LARGE1 Products |
| Related Target B | Laminin Subunit Alpha 2 (LAMA2) Primary extracellular matrix ligand for glycosylated alpha-dystroglycan. |
View LAMA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent binding (Matriglycan) | HEK293 Expressed DAG1 with native post-translational O-glycosylation verified by Theoretical MW shift. |
| Subunit specific screening (Alpha vs. Beta DG) | Truncated ECD-Fc fusions and specific intracellular domain constructs available with >95% purity. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live DAG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DAG1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to gene therapies, glycan-modifying enzymes, and targeted oncology constructs. As first-generation therapies for muscular dystrophies reach the clinic, the next wave of R&D is targeting DAG1-mediated viral entry (such as Lassa virus) and its role as a tumor suppressor or cell-surface marker in specific epithelial malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / AAV | Sarepta Therapeutics, Solid Biosciences | Dystroglycanopathy, LGMD | Functional validation of DAG1 glycosylation (Need LARGE1 co-expression / LAMA2 binding assays) |
| Monoclonal Antibody | Academic & Biotech Consortia | Lassa Fever, Viral Entry Inhibition | Conformational epitope mapping (Need Lentivirus for Stable Cell Line expression) |
| Small Molecule / Chaperone | PTC Therapeutics, Biomarin | Congenital Muscular Dystrophies | High-throughput screening of DAG1 surface presentation (Need Sequence Verified full-length ORF) |